Primecap Management CO Nektar Therapeutics Transaction History

Primecap Management CO

$132 Billion
Q1 2024

A detailed history of Primecap Management CO transactions in Nektar Therapeutics stock. As of the latest transaction made, Primecap Management CO holds 6,966,647 shares of NKTR stock, worth $8.64 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,966,647

Previous 7,001,747 0.5%

Holding current value

$8.64 Million

Previous $3.92 Million 65.26%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$0.49 - $0.96 $17,199 - $33,696	-35,100 Reduced 0.5%	6,966,647 $6.48 Million
Q4 2023 Feb 09, 2024	SELL	$0.42 - $0.57 $82,419 - $111,854	-196,236 Reduced 2.73%	7,001,747 $3.92 Million
Q3 2023 Nov 13, 2023	SELL	$0.51 - $1.05 $485,465 - $999,487	-951,893 Reduced 11.68%	7,197,983 $4.32 Million
Q2 2023 Aug 11, 2023	SELL	$0.53 - $1.03 $1.77 Million - $3.43 Million	-3,333,150 Reduced 29.03%	8,149,876 $4.73 Million
Q1 2023 May 15, 2023	SELL	$0.64 - $3.15 $2.67 Million - $13.2 Million	-4,176,027 Reduced 26.67%	11,483,026 $8.04 Million

Q4 2022 Feb 13, 2023	SELL	$2.03 - $4.28 $1.55 Million - $3.27 Million	-763,390 Reduced 4.65%	15,659,053 $35.4 Million
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.14 $391,792 - $662,438	-128,879 Reduced 0.78%	16,422,443 $52.6 Million
Q2 2022 Aug 11, 2022	SELL	$3.17 - $6.17 $1.62 Million - $3.15 Million	-510,500 Reduced 2.99%	16,551,322 $62.9 Million
Q1 2022 May 11, 2022	SELL	$4.16 - $13.72 $1.46 Million - $4.81 Million	-350,600 Reduced 2.01%	17,061,822 $92 Million
Q4 2021 Feb 11, 2022	SELL	$10.83 - $18.41 $6.14 Million - $10.4 Million	-567,100 Reduced 3.15%	17,412,422 $235 Million
Q3 2021 Nov 12, 2021	SELL	$13.07 - $18.84 $1.34 Million - $1.93 Million	-102,250 Reduced 0.57%	17,979,522 $323 Million
Q2 2021 Aug 10, 2021	SELL	$16.52 - $20.4 $1.38 Million - $1.71 Million	-83,597 Reduced 0.46%	18,081,772 $310 Million
Q1 2021 May 14, 2021	SELL	$16.56 - $25.46 $4.55 Million - $7 Million	-275,030 Reduced 1.49%	18,165,369 $363 Million
Q4 2020 Feb 08, 2021	SELL	$15.77 - $19.03 $6.72 Million - $8.11 Million	-426,230 Reduced 2.26%	18,440,399 $313 Million
Q3 2020 Nov 13, 2020	SELL	$16.59 - $24.79 $8.96 Million - $13.4 Million	-539,970 Reduced 2.78%	18,866,629 $313 Million
Q2 2020 Aug 13, 2020	SELL	$16.86 - $23.44 $18.1 Million - $25.2 Million	-1,076,320 Reduced 5.25%	19,406,599 $449 Million
Q1 2020 May 14, 2020	BUY	$14.47 - $27.96 $5.83 Million - $11.3 Million	402,571 Added 2.0%	20,482,919 $366 Million
Q4 2019 Feb 14, 2020	BUY	$15.87 - $23.12 $15.2 Million - $22.1 Million	957,126 Added 5.01%	20,080,348 $433 Million
Q3 2019 Nov 13, 2019	BUY	$16.91 - $36.27 $554,648 - $1.19 Million	32,800 Added 0.17%	19,123,222 $348 Million
Q2 2019 Aug 14, 2019	SELL	$31.0 - $36.3 $8.23 Million - $9.63 Million	-265,400 Reduced 1.37%	19,090,422 $679 Million
Q1 2019 May 14, 2019	SELL	$31.58 - $46.35 $1.4 Million - $2.05 Million	-44,200 Reduced 0.23%	19,355,822 $650 Million
Q4 2018 Feb 12, 2019	SELL	$30.43 - $56.65 $23 Million - $42.8 Million	-754,900 Reduced 3.75%	19,400,022 $638 Million
Q3 2018 Nov 13, 2018	SELL	$46.46 - $68.49 $34.8 Million - $51.2 Million	-748,000 Reduced 3.58%	20,154,922 $1.23 Billion
Q2 2018 Aug 13, 2018	SELL	$46.25 - $104.45 $7.35 Million - $16.6 Million	-158,973 Reduced 0.75%	20,902,922 $1.02 Billion
Q1 2018 May 14, 2018	SELL	$57.4 - $108.44 $74.4 Million - $140 Million	-1,295,627 Reduced 5.8%	21,061,895 $2.24 Billion
Q4 2017 Feb 13, 2018	SELL	$23.02 - $60.5 $18.1 Million - $47.5 Million	-784,700 Reduced 3.39%	22,357,522 $1.34 Billion
Q3 2017 Nov 13, 2017	BUY	$17.79 - $24.0 $412 Million - $555 Million	23,142,222	23,142,222 $555 Million

Others Institutions Holding NKTR

# of Institutions

128

Shares Held

111M

Call Options Held

150K

Put Options Held

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $232M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Primecap Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Primecap Management CO with notifications on news.

Account

Primecap Management CO Nektar Therapeutics Transaction History